In mutant KRAS-driven murine models of NSCLC, genetic deletion of PTPN11 suppressed tumor development, while the dual inhibition of SHP2 and MEK resulted in sustained tumor growth control in murine- and human patient-derived organoids and xenograft models of NSCLC [103]. Here, MAP2K7 is linked to neoplasm.